Cart
sales@molnova.com
VUF 10166
CAS No. 155584-74-0
VUF 10166 ( —— )
Catalog No. M17335 CAS No. 155584-74-0
VUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 37 | In Stock |
|
| 10MG | 59 | In Stock |
|
| 25MG | 112 | In Stock |
|
| 100MG | 299 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVUF 10166
-
NoteResearch use only, not for human use.
-
Brief DescriptionVUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
-
DescriptionVUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor5-HT3A; 5-HT3AB
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number155584-74-0
-
Formula Weight262.74
-
Molecular FormulaC13H15ClN4
-
Purity98%
-
Solubility——
-
SMILESCN1CCN(CC1)C1=NC2=CC=CC=C2N=C1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Thompson AJ, et al. J Pharmacol Exp Ther, 2012, 341(2), 350-9.
molnova catalog
related products
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
Naquotinib
Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.
-
Olmutinib
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
